Literature DB >> 25437496

Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case-control study.

Jia-Feng Wang1, Jin-Bao Li, Yan-Jun Zhao, Wen-Jing Yi, Jin-Jun Bian, Xiao-Jian Wan, Ke-Ming Zhu, Xiao-Ming Deng.   

Abstract

BACKGROUND: Recent studies have shown that neutrophils may display an antigen-presenting function and inhibit lymphocyte proliferation by expressing programmed cell death 1 ligand 1 (PD-L1). The current study was performed to investigate the effect of neutrophils and their pathophysiological significance during sepsis.
METHODS: Neutrophil PD-L1 expression was determined in both septic mice (n = 6) and patients (n = 41). Neutrophils from septic mice were subtyped into PD-L1 and PD-L1 populations to determine their phenotypes and functions. Septic neutrophils were cocultured with lymphocytes to observe the effect of septic neutrophils on lymphocyte apoptosis.
RESULTS: The PD-L1 level on neutrophils from septic mice was significantly up-regulated (21.41 ± 4.76%). This level increased with the progression of sepsis and the migration of neutrophils from the bone marrow to the blood and peritoneal cavity. The percentages of CD11a, CD62L, and C-C chemokine receptor type 2 were lower, whereas the percentages of CD16 and CD64 were higher on PD-L1 neutrophils than on PD-L1 neutrophils. The migratory capacity of PD-L1 neutrophils was compromised. Septic neutrophils induced lymphocyte apoptosis via a contact mechanism, and this process could be reversed by anti-PD-L1 antibody. PD-L1 was also up-regulated on neutrophils from patients with severe sepsis (14.6% [3.75%, 42.1%]). The levels were negatively correlated with the monocyte human leukocyte antigen-DR level and positively correlated with the severity of septic patients. Neutrophil PD-L1 was a predictor for the prognosis of severe sepsis, with an area of 0.74 under the receiver operating curve.
CONCLUSIONS: PD-L1 is up-regulated on neutrophils during sepsis, which may be related to sepsis-induced immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25437496     DOI: 10.1097/ALN.0000000000000525

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  41 in total

Review 1.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

2.  Neutrophil Vaccination Dynamics and Their Capacity To Mediate B Cell Help in Rhesus Macaques.

Authors:  Thomas Musich; Mohammad Arif Rahman; Venkatramanan Mohanram; Leia Miller-Novak; Thorsten Demberg; David J Venzon; Barbara K Felber; Genoveffa Franchini; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2018-09-14       Impact factor: 5.422

3.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

Review 4.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality?

Authors:  Matthew J Delano; Peter A Ward
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

5.  Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice.

Authors:  Shumin Xu; Qian Yang; Jianwen Bai; Tianzhu Tao; Lunxian Tang; Yaping Chen; Chun-Shiang Chung; Eleanor A Fallon; Alfred Ayala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-01-29       Impact factor: 5.464

Review 6.  The immune system's role in sepsis progression, resolution, and long-term outcome.

Authors:  Matthew J Delano; Peter A Ward
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 7.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

8.  Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.

Authors:  Andriani C Patera; Anne M Drewry; Katherine Chang; Evan R Beiter; Dale Osborne; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2016-09-26       Impact factor: 4.962

Review 9.  IMMUNE CELL PHENOTYPE AND FUNCTION IN SEPSIS.

Authors:  Thomas Rimmelé; Didier Payen; Vincenzo Cantaluppi; John Marshall; Hernando Gomez; Alonso Gomez; Patrick Murray; John A Kellum
Journal:  Shock       Date:  2016-03       Impact factor: 3.454

10.  Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Elliott D Crouser; Greg S Martin; Timothy Albertson; Raquel R Bartz; Scott C Brakenridge; Matthew J Delano; Pauline K Park; Michael W Donnino; Mark Tidswell; Florian B Mayr; Derek C Angus; Craig M Coopersmith; Lyle L Moldawer; Ian M Catlett; Ihab G Girgis; June Ye; Dennis M Grasela
Journal:  Intensive Care Med       Date:  2019-10-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.